Absolute PET Myocardial Blood Flow Quantification in the Diagnosis and Risk Stratification of Coronary Microvascular Dysfunction
- 1Department of Nuclear Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230001 Hefei, Anhui, China
- 2Department of Cardiovascular Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230001 Hefei, Anhui, China
Abstract
Invasive coronary angiography reveals non-obstructive coronary artery disease in approximately 60% of patients. Meanwhile, up to two-thirds of these individuals have coronary microvascular dysfunction (CMD), which often explains their symptoms. CMD is a clinically important condition that affects women with chronic coronary syndrome much more often than men. In these patients, impaired myocardial flow reserve (MFR) is a reliable predictor of adverse clinical outcomes, even in the absence of visible perfusion defects. Positron emission tomography (PET) enables quantification of myocardial blood flow (MBF) and MFR, both of which play critical roles in the diagnosis of CMD, support accurate risk stratification, and may be useful for monitoring treatment response. Emerging radiotracers, such as 18F-flurpiridaz, offer favorable pharmacokinetics and practical logistical benefits, thereby improving clinical access to PET imaging. Parallel advances, including artificial intelligence-powered analytical tools and total-body PET, are expected to enhance reproducibility and efficiency, further integrating myocardial flow assessment into routine clinical workflows. As technology and evidence continue to evolve, PET-based MBF quantification is likely to become an essential tool in precision cardiovascular care, effectively closing the gap between physiology and clinical decision-making. This narrative review aims to provide an overview of coronary microvascular pathophysiology and the most up-to-date evidence regarding the use of PET-derived MBF quantification in the diagnosis and management of patients with CMD.
Related
- Non-Invasive Assessment of Coronary Microvascular Dysfunction: From Flow Quantification to Clinical Decision Making
- Coronary Microvascular Dysfunction in ANOCA and INOCA: From Pathophysiological Endotypes to Precision Diagnosis and Treatment.
- Early detection of myocardial fibrosis in patients with coronary microvascular dysfunction in the absence of late enhancement: role of T1 mapping and extracellular volume analysis.
- SGLT2i protects against myocardial I/R-induced coronary microvascular injury by inhibiting glycocalyx degradation
- Chronic Inflammation and Coronary Microvascular Dysfunction
BibTeX
@article{wen2026absolute,
title = {{Absolute PET Myocardial Blood Flow Quantification in the Diagnosis and Risk Stratification of Coronary Microvascular Dysfunction}},
author = {Runze Wen and Dan Li and Xuemei Wang},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.31083/rcm53499},
url = {https://doi.org/10.31083/rcm53499},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Absolute PET Myocardial Blood Flow Quantification in the Diagnosis and Risk Stratification of Coronary Microvascular Dysfunction
AU - Runze Wen
AU - Dan Li
AU - Xuemei Wang
PY - 2026
DA - 2026/10/12
JO - Reviews in Cardiovascular Medicine
DO - 10.31083/rcm53499
UR - https://doi.org/10.31083/rcm53499
AB - Invasive coronary angiography reveals non-obstructive coronary artery disease in approximately 60% of patients. Meanwhile, up to two-thirds of these individuals have coronary microvascular dysfunction (CMD), which often explains their symptoms. CMD is a clinically important condition that affects women with chronic coronary syndrome much more often than men. In these patients, impaired myocardial flow reserve (MFR) is a reliable predictor of adverse clinical outcomes, even in the absence of visible perfusion defects. Positron emission tomography (PET) enables quantification of myocardial blood flow (MBF) and MFR, both of which play critical roles in the diagnosis of CMD, support accurate risk stratification, and may be useful for monitoring treatment response. Emerging radiotracers, such as 18F-flurpiridaz, offer favorable pharmacokinetics and practical logistical benefits, thereby improving clinical access to PET imaging. Parallel advances, including artificial intelligence-powered analytical tools and total-body PET, are expected to enhance reproducibility and efficiency, further integrating myocardial flow assessment into routine clinical workflows. As technology and evidence continue to evolve, PET-based MBF quantification is likely to become an essential tool in precision cardiovascular care, effectively closing the gap between physiology and clinical decision-making. This narrative review aims to provide an overview of coronary microvascular pathophysiology and the most up-to-date evidence regarding the use of PET-derived MBF quantification in the diagnosis and management of patients with CMD.
SN - 1530-6550
SN - 2153-8174
ER -